business
India's Biocon on Generic GLP-1 Push
Biocon CEO, Shreehas Tambe, discusses their push into the generic GLP-1 market, after Novo Nordisk cut prices of its blockbuster weight-loss and diabetes medications in India. He also spoke about the company's latest set of earnings on Insight with Haslinda Amin. (Source: Bloomberg)
Read full story on Bloomberg Markets → More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop